NFYAP1: A Potential Drug Target and Biomarker (G100130677)

Target Name: NFYAP1

NCBI ID: G100130677

NFYAP1

Other Name(s): Nuclear transcription factor Y, alpha pseudogene 1 | nuclear transcription factor Y subunit alpha pseudogene 1 | NFYAP

NFYAP1: A Potential Drug Target and Biomarker

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has identifiedNFYAP1, a gene that has been associated with the development of various diseases, as a potential drug target. The gene, which stands for neurofibromatosis-related YAP/TAZ gene, has been found to be over-expressed in various tissues, including brain, heart, and pancreas, and has been linked to the development of neurofibromatosis, a genetic disorder that causes tumors, as well as other diseases.

NFYAP1 is a protein that is expressed in various tissues and is involved in the development and maintenance of neural stem cells. It is a key regulator of the TGF-β pathway, a well-known mechanism that is involved in cell growth, differentiation, and survival. The TGF-β pathway plays a crucial role in the development and maintenance of tissues, including brain, and is often disrupted in neurofibromatosis.

Research has shown thatNFYAP1 is involved in the development and progression of various diseases, including neurofibromatosis, Alzheimer's disease, and cancer. It has also been linked to the development of other conditions, including heart disease and diabetes.

One of the key challenges in studyingNFYAP1 is its involvement in multiple diseases, which can make it difficult to identify its true role in each of these conditions. However, research has shown that NFYAP1 is involved in the development and progression of neurofibromatosis, a genetic disorder that is characterized by the formation of tumors in the brain and other tissues.

In addition to its involvement in neurofibromatosis, NFYAP1 has also been linked to the development of other diseases, including Alzheimer's disease, cancer, and heart disease. Studies have shown that NFYAP1 is over-expressed in various tissues, including brain, heart, and pancreas, and is involved in the development and progression of these diseases.

The potential drug targets for NFYAP1 are vast, as it is involved in the TGF-β pathway, which is a critical regulator of cell growth, differentiation, and survival. Researchers are interested in studying how NFYAP1 functions as a drug target and how it can be used to treat various diseases.

One of the most promising potential drug targets for NFYAP1 is its role in the development and progression of neurofibromatosis. Neurofibromatosis is a genetic disorder that is characterized by the formation of tumors in the brain and other tissues. It is a progressive disease that can cause significant disability and quality of life.

Research has shown that NFYAP1 is involved in the development and progression of neurofibromatosis and is a key regulator of the TGF-β pathway. Therefore,NFYAP1 could be a promising drug target for the treatment of neurofibromatosis. Researchers are interested in studying the effects of drugs that can inhibit the activity of NFYAP1 and how this can be used to treat neurofibromatosis.

Another potential drug target for NFYAP1 is its role in the development and progression of cancer. Studies have shown that NFYAP1 is involved in the development and progression of various cancers, including breast, ovarian, and prostate cancers. Therefore, NFYAP1 could be a promising drug target for the treatment of cancer.

In addition to its involvement in neurofibromatosis and cancer, NFYAP1 has also been linked to the development of other diseases, including heart disease and diabetes. Studies have shown that NFYAP1 is involved in the development and progression of these diseases and could be a potential drug target

Protein Name: Nuclear Transcription Factor Y Subunit Alpha Pseudogene 1

The "NFYAP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NFYAP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets